A head-to-head comparison trial of ARBs vs ACEis exhibited no difference in outcomes except for fewer drug withdrawals due to adverse effects with ARBs (RR, 0.72; 95% CI, 0.65-0.81).1
In another study, ARBs had significantly lower risks of angioedema, cough, pancreatitis, and GI bleeding than patients on ACEis.2
Angioedema associated with ACEis was common (HR = 3.31; 95% CI, 2.55–4.51; P < .01), versus ARBs. Although rare, it remains an adverse event of concern as occasionally it can be fatal.
In New Zealand, Pharmac fully funds Losartan and Candesartan, so there is no longer any funding barrier to ARB usage.
References:
As published in NZ Doctor
As published in Research Review
